Revenue (TTM) Chart

View Revenue (TTM) for MYGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue (TTM) Chart
Start Trial

Historical Revenue (TTM) Data

View and export this data back to 1999. Start Trial.
Date Value
June 30, 2026 806.60M
March 31, 2026 829.00M
December 31, 2025 824.50M
September 30, 2025 825.30M
June 30, 2025 832.90M
March 31, 2025 831.30M
December 31, 2024 837.60M
September 30, 2024 823.60M
June 30, 2024 802.20M
March 31, 2024 774.20M
December 31, 2023 753.20M
September 30, 2023 734.40M
June 30, 2023 698.90M
March 31, 2023 694.70M
December 31, 2022 678.40M
September 30, 2022 661.40M
June 30, 2022 672.30M
March 31, 2022 682.40M
December 31, 2021 690.60M
September 30, 2021 623.00M
June 30, 2021 619.70M
March 31, 2021 625.40M
June 30, 2020 638.60M
March 31, 2020 760.80M
December 31, 2019 813.40M
Date Value
September 30, 2019 835.10M
June 30, 2019 851.10M
March 31, 2019 829.60M
December 31, 2018 796.10M
September 30, 2018 767.20M
June 30, 2018 743.70M
March 31, 2018 750.30M
December 31, 2017 764.10M
September 30, 2017 772.70M
June 30, 2017 771.40M
March 31, 2017 757.40M
December 31, 2016 751.00M
September 30, 2016 747.80M
June 30, 2016 753.80M
March 31, 2016 757.20M
December 31, 2015 746.68M
September 30, 2015 737.78M
June 30, 2015 723.12M
March 31, 2015 721.98M
December 31, 2014 724.92M
September 30, 2014 744.59M
June 30, 2014 778.22M
March 31, 2014 763.57M
December 31, 2013 737.11M
September 30, 2013 682.19M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (TTM) Range, Past 5 Years

View Revenue (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (TTM) Benchmarks

View Revenue (TTM) Benchmarks
Start Trial
Natera, Inc. 2.707B
Sera Prognostics, Inc. 0.07M
BioRestorative Therapies, Inc. 0.3579M
CareDx, Inc. 458.09M
Exagen, Inc. 71.12M